Videos

Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 5 minutes]

In this episode of MEDcast, Dr Krieger, Dr Brandstadter, and Dr Bove discuss MS care in patients who are considering pregnancy. They highlight treatment options, monitoring recommendations during and after pregnancy, as well as other crucial considerations when caring for patients with childbearing goals.

The duo from Indiana University School of Medicine discussed the ongoing research initiatives to better understand sleep disorders among pediatrics, and ways to improve approaches like cognitive behavioral therapy. [WATCH TIME: 4 minutes]

The postdoctoral researcher in the department of neurology at John Hopkins School of Medicine talked about indole-3-lactate as a signaling molecule in the gut-brain axis and its potential as a treatment for MS. [WATCH TIME: 5 minutes]

The undergraduate program director at the University of South Carolina discussed outdated teaching methods used in neurology, and the need to provide different hands-on approaches to students. [WATCH TIME: 5 minutes]

The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending July 8, 2023. [WATCH TIME: 3 minutes]

Nicholas Silvestri, MD, FAAN, reviews investigational agents and ongoing studies in the pipeline, as well as advice for earlier engagement and evaluation of patients for myasthenia gravis to hasten treatment.

Nicholas Silvestri, MD, FAAN, shares clinical results with eculizumab and ravulizumab, as well as which patients should use biologics and when during the treatment journey.

The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]

Nicholas Silvestri, MD, FAAN, discusses neonatal Fc receptor and how it contributes to the pathophysiology of myasthenia gravis, as well as the study design, efficacy, safety, and quality-of-life data with efgartigimod phase 3 ADAPT study.

The duo from Indiana University School of Medicine provided perspective on the reasons for why cognitive behavioral therapy used for insomnia need to be adjusted in adolescents with the sleep disorder. [WATCH TIME: 3 minutes]

The assistant professor at Hunter College discussed the approach of systematically localizing symptoms in patients with multiple sclerosis for diagnosis based on a clinical workshop. [WATCH TIME: 5 minutes]

In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s disease. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.

Daniel E. Kremens, MD, JD, reviews the underlying pathophysiological factors that contribute to OFF episodes.

Daniel E. Kremens, MD, JD, discusses the standard of care for patients with Parkinson disease and when patients start to experience OFF episodes.

The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided perspective on the current major research priorities for the treatment of restless legs syndrome. [WATCH TIME: 3 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about how research in essential tremor is revolutionizing the diagnosis and understanding of the movement disorder. [WATCH TIME: 5 minutes]

Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]

The professor of neurology at UMass Chan School of Medicine discussed the various impacts Daylight Savings Time has on sleep quality and overall health in children and adolescents. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

Nicholas Silvestri, MD, FAAN, reviews the standard of care and initial treatments patients with myasthenia gravis (MG) receive, as well as several new treatment options that have recently become available for MG (eculizumab, efgartigimod alfa-fcab, ravulizumab-cwvz).

Nicholas Silvestri, MD, FAAN, discusses the level of awareness of myasthenia gravis (MG) and generalized MG among primary care physicians and the public, and the type of harm patients might sustain if they do not receive timely treatment.

The chief scientific officer at Liberate Bio discussed how through the advancement of nonviral delivery technologies and nucleic acid therapeutics, genetic medicines can potentially bring relief to patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University talked about the significance of diversity and the health disparities faced by patients with multiple sclerosis in the LGBTQ+ community. [WATCH TIME: 3 minutes]

The professor of neurology at the University of California, Irvine, talked about social determinants of health in Alzheimer disease and the importance of having diverse populations in clinical trials. [WATCH TIME: 4 minutes]